Only know one person who was briefly prescribed that stuff.
It's an absolutely classic example of the 'indication creep' I have mentioned several times.
When dealing with Parkinson's disease, a 'less than optimal' side-effect profile is acceptable since, after all, the outcomes for people with that illness are the same - it's not quite but almost palliative (given UK law specifies palliative as life-expectancy of <6 months and with Parkinsons, that may or may not be the case.
But some marketing manager somehow got it licenced to treat RLS. At least in the UK the indication is 'severe RLS' as a nod to those side-effects.